Dr Jitendra briefed about new drug for emergency use in COVID

Union Minister Dr Jitendra Singh discussing various aspects of current medical research on COVID-19, through Video Conference, on Monday.
Union Minister Dr Jitendra Singh discussing various aspects of current medical research on COVID-19, through Video Conference, on Monday.

Excelsior Correspondent

NEW DELHI, May 4 : Union Minister Dr Jitendra Singh was today briefed about the new drug, Remdesivir, approved by FDA (Food and Drug Administration) for emergency use in COVID 19 patients. The drug was recently approved for emergency use in the hospital setting in ICU under medical supervision and was claimed to reduce the mortality rate in such cases.
In a Video Conference interaction about the current research going on with regard to the medical and other aspects of COVID 19, senior scientists of the Council of Scientific & Industrial Research (CSIR) led by Dr Shekhar C. Mande, Director General CSIR and Dr Ram Vishwakarma, Director CSIR IIIM Jammu updated Dr Jitendra Singh about different aspects of Remdesivir and also informed that the CSIR-IICT has done synthesis of the drug on a gram scale including Key Starting Materials (KSMs ) on the kilo scale. Technology demonstration was going on in India, it was stated.
Dr Jitendra Singh was informed that CSIR and Cadila Pharmaceuticals under the NMITLI Program are going ahead with the clinical trials of Mw based Sepsivac. Drugs Controller General of India has approved three clinical trial protocols for three different conditions of patients inflicted with Corona virus. In another development, a phytopharmaceutical formulation ACQH is about to get the nod from the regulators for the clinical trial.
Dr Jitendra Singh appreciated CSIR for carrying out Corona sample testing in 14 of its laboratories across the country including in Jammu & Kashmir and Northeast. Innovation through high science being carried out include CRISPR Cas based paper assay, Nested PCR, and NGS based large sample testing. These innovations may bring a paradigm shift in the way testing will be done in the country.
CSIR has set up five technology verticals for addressing the emerging situation due to pandemic. An aerospace laboratory is helping in Corona mitigation by using its knowledge base to develop a BiPAP ventilator in a very short span of 35 days. Further, CSIR-NAL & MAFL have jointly developed a coverall and have received an order of 50,000 pieces from HLL and are gearing up to produce 30,000 pieces/day.
The Minister appreciated the strategy adopted by CSIR by bringing different expertise at its disposal to mount a concerted multi-pronged approach to fight the menace of coronavirus

LEAVE A REPLY

Please enter your comment!
Please enter your name here